Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD

Blood (2019) 134 (Supplement_1): 1907.

https://doi.org/10.1182/blood-2019-123652

Published: 2019

Journal Articles

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Jeong A Park, MD PhD, Hong fen Guo, PhD, Hong Xu, PhD, Nai-Kong V. Cheung, MD PhD

Blood (2019) 134 (Supplement_1): 1959.

https://doi.org/10.1182/blood-2019-131325

Published: 2019

Journal Articles

Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade

Shadi Swaidani, MD PhD, Joanna Roopkumar, MBBS, MPH, Young Jun-Shim, PhD, Cathy Charles, Slato Paul, Suman Kundu, MBA, Pauline Funchain, MD, Patricia Rayman, Paul G. Pavicic, C. Marcela Diaz-Montero, PhD, Alok A Khorana, MD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 3648.

https://doi.org/10.1182/blood-2019-130911

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD

Blood (2019) 134 (Supplement_1): 2917.

https://doi.org/10.1182/blood-2019-123664

Published: 2019

Journal Articles

Venous Thromboembolism in Cancer Patients Receiving Immunotherapy

Joanna Roopkumar, MBBS, MPH, Ann S. Kim, BA, Thapa Bicky, MD, Brian P. Hobbs, PhD, Alok A. Khorana, MD

Blood (2018) 132 (Supplement 1): 2510.

https://doi.org/10.1182/blood-2018-99-116439

Published: 2018

Journal Articles

End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma

Caron A. Jacobson, MD MMSc, Frederick L. Locke, MD, David B. Miklos, MD PhD, Alex F. Herrera, MD, Jason R. Westin, MD, Jennifer Lee, John M. Rossi, MS, Lianqing Zheng, PhD, Mauro P. Avanzi, MD, Zachary J. Roberts, MD, PhD, Jennifer Sun, MS

Blood (2018) 132 (Supplement 1): 4192.

https://doi.org/10.1182/blood-2018-99-111523

Published: 2018

Journal Articles

PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis

Aaron T. Gerds, MDMS, Bart L Scott, MD, Peter L Greenberg, MD, Samer K. Khaled, MD, Tara L Lin, MD, Daniel A Pollyea, MD, Amit Verma, MD, Monique Dail, Cherie Green, Connie Ma, Bruno C Medeiros, Patrick Phuong, Michael Wenger, Mark Yan, William B. Donnellan, MD

Blood (2018) 132 (Supplement 1): 466.

https://doi.org/10.1182/blood-2018-99-118577

Published: 2018

Journal Articles

The New Landscape of Checkpoint Inhibitors in China

Chien-Shing Chen, MD PhD

Blood (2018) 132 (Supplement 1): 5855.

https://doi.org/10.1182/blood-2018-99-111666

Published: 2018

Journal Articles

Autoimmune Hemolytic Anemia and Checkpoint Inhibitors: 68 Cases from the FDA Database and Critical Review

Georges Tanios, MD, Peter B Doley, Reinhold Munker, MD

Blood (2018) 132 (Supplement 1): 2324.

https://doi.org/10.1182/blood-2018-99-111724

Published: 2018

Journal Articles

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Hearn Jay Cho, MD, Luciano J Costa, MD PhD, Faith E. Davies, MD, Natalia Neparidze, MD, Ravi Vij, Yuning Feng, Anastasia Teterina, Elisabeth Wassner Fritsch, Michael Wenger, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 597.

https://doi.org/10.1182/blood-2018-99-114960

Published: 2018

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2018-99-116678

Published: 2018

Journal Articles

Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience

Sami Ibrahimi, MD, Michael Machiorlatti, Sara K. Vesely, PhD MPH, Midhun Malla, MBBS, Falgun Modhia, MD, Shari A. Jones, MD PhD, Darwin Roman, MD, Mohamad A. Cherry, MDMS

Blood (2017) 130 (Supplement 1): 4864.

https://doi.org/10.1182/blood.V130.Suppl_1.4864.4864

Published: 2017

Journal Articles

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Frederick L. Locke, MD, Jason R. Westin, MD, David B. Miklos, MD PhD, Alex F. Herrara, MD, Caron A. Jacobson, MD, Jennifer Lee, John M. Rossi, MS, Adrian Bot, MD PhD, Allen Xue, PhD, Lynn Navale, MS, Jeff S. Aycock, Jeffrey S. Wiezorek, MD MS, Zachary J. Roberts, MD PhD

Blood (2017) 130 (Supplement 1): 2826.

https://doi.org/10.1182/blood.V130.Suppl_1.2826.2826

Published: 2017

Journal Articles

Analysis of Outcome of Patients Treated with Anti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia

Sarbajit Mukherjee, MD, Michael Machiorlatti, Bilal Khalid, MD, Gabriel Souza Vidal, MD, Jennifer Holter Charkrabarty, MD, Mohamad A. Cherry, MDMS

Blood (2017) 130 (Supplement 1): 3594.

https://doi.org/10.1182/blood.V130.Suppl_1.3594.3594

Published: 2017

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Anas Younes, MD, Burke M. John, Catherine S Diefenbach, Silvia Ferrari, Cyrus Kahn, Jeffrey P. Sharman, MD, Monica Tani, Chaitra S. Ujjani, MD, Umberto Vitolo, MD, Sam Yuen, Paul Woodard, Kirsten Mundt, Günter Fingerle-Rowson, Surya Chitra, Gila Sellam, Rodica Morariu-Zamfir, Michael Gilbertson

Blood (2017) 130 (Supplement 1): 481.

https://doi.org/10.1182/blood.V130.Suppl_1.481.481

Published: 2017

Journal Articles

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brian G. Till, MD, Steven I. Park, MD, Leslie L. Popplewell, MD, Andre Goy, MD, Elicia Penuel, PhD, Jeffrey M Venstrom, MD, Bo Liu, Guenter Fingerle-Rowson, MD PhD, John Byon, MD PhD, Paul Woodard, MD, M. Lia Palomba, MD

Blood (2015) 126 (23): 5104.

https://doi.org/10.1182/blood.V126.23.5104.5104

Published: 2015

NARROW

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

Venous Thromboembolism in Cancer Patients Receiving Immunotherapy

End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma

PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis

The New Landscape of Checkpoint Inhibitors in China

Autoimmune Hemolytic Anemia and Checkpoint Inhibitors: 68 Cases from the FDA Database and Critical Review

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Analysis of Outcome of Patients Treated with Anti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only